Ranimustine

Ranimustine

SCHEMBL5506489

CO[C@H]1O[C@H](CNC(=O)N(CCCl)N=O)[C@@H](O)[C@H](O)[C@H]1O.O=NN(CCCl)C(=O)NC1CCCCC1

nearest known ligand 0.58

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA2A P08913 2/20 0.58
PDE4A P27815 1/20 0.58
ADRA1A P35348 1/20 0.58
ALDH1A1 P00352 2/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
MEN1 O00255 1/20 0.38
ABCB11 O95342 1/20 0.38
GSR P00390 1/20 0.38
TSHR P16473 1/20 0.38
HTT P42858 1/20 0.38
BLM P54132 1/20 0.38
PMP22 Q01453 1/20 0.38
KMT2A Q03164 1/20 0.38
CA1 P00915 4/20 0.37
CA2 P00918 4/20 0.37
CA9 Q16790 4/20 0.37
G6PD P11413 1/20 0.35
MMP9 P14780 1/20 0.34
MMP12 P39900 1/20 0.34
EPHX2 P34913 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ranimustine SCHEMBL699970 0.93 ADRA2A (0.61) ADRA2APDE4AADRA1AALDH1A1SMN1; SMN2
Ranimustine SCHEMBL10079210 0.90 ALDH1A1 (0.46) ADRA2APDE4AADRA1AALDH1A1SMN1; SMN2
Ranimustine SCHEMBL15474340 0.90 ALDH1A1 (0.46) ADRA2APDE4AADRA1AALDH1A1SMN1; SMN2
Ranimustine SCHEMBL22595035 0.90 ALDH1A1 (0.46) ADRA2APDE4AADRA1AALDH1A1SMN1; SMN2
Ranimustine SCHEMBL1650173 0.90 ALDH1A1 (0.46) ADRA2APDE4AADRA1AALDH1A1SMN1; SMN2
Ranimustine SCHEMBL11757182 0.90 ALDH1A1 (0.46) ADRA2APDE4AADRA1AALDH1A1SMN1; SMN2
Ranimustine SCHEMBL6429694 0.90 ALDH1A1 (0.46) ADRA2APDE4AADRA1AALDH1A1SMN1; SMN2
Ranimustine SCHEMBL8333 0.90 ALDH1A1 (0.46) ADRA2APDE4AADRA1AALDH1A1SMN1; SMN2
Ranimustine SCHEMBL2678774 0.84 PYGB (0.44) ADRA2APDE4AADRA1AALDH1A1SMN1; SMN2
Ranimustine SCHEMBL4197596 0.82 ALDH1A1 (0.37) ADRA2APDE4AADRA1AALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1796602-A2 MULTIFUNCTIONAL COMPOUNDS FOR FORMING CROSSLINKED BIOMATERIALS AND METHODS OF PREPARATION AND USE Angiotech Pharmaceuticals (US), Inc. (US) 2007-06-20 EP disclosed
EP-1687041-A2 SOFT TISSUE IMPLANTS AND ANTI-SCARRING AGENTS Angiotech International AG (CH) 2006-08-09 EP disclosed
WO-2005051871-A9 IMPLANTABLE SENSORS AND IMPLANTABLE PUMPS AND ANTI-SCARRING AGENTS ANGIOTECH INT AG (CH) 2006-07-27 WO disclosed
WO-2006078282-A2 COMPOSITIONS AND SYSTEMS FOR FORMING CROSSLINKED BIOMATERIALS AND ASSOCIATED METHODS OF PREPARATION AND USE ANGIOTECH BIOMATERIALS CORPORATION (US) 2006-07-27 WO disclosed
WO-2006055008-A2 IMPLANTABLE SENSORS AND IMPLANTABLE PUMPS AND ANTI-SCARRING AGENTS ANGIOTECH INTERNATIONAL AG (CH) 2006-05-26 WO disclosed
WO-2006034128-A2 MULTIFUNCTIONAL COMPOUNDS FOR FORMING CROSSLINKED BIOMATERIALS AND METHODS OF PREPARATION AND USE ANGIOTECH BIOMATERIALS CORPORATION (US) 2006-03-30 WO disclosed
EP-1583561-A3 TISSUE REACTIVE COMPOUNDS AND COMPOSITIONS AND USES THEREOF ANGIOTECH INTERNATIONAL AG (CH) 2005-12-07 EP disclosed
EP-1594459-A2 DRUG DELIVERY FROM RAPID GELLING POLYMER COMPOSITION ANGIOTECH INTERNATIONAL AG (CH) 2005-11-16 EP disclosed
EP-1583561-A2 TISSUE REACTIVE COMPOUNDS AND COMPOSITIONS AND USES THEREOF ANGIOTECH INTERNATIONAL AG (CH) 2005-10-12 EP disclosed
WO-2005051316-A2 POLYMER COMPOSITIONS AND METHODS FOR THEIR USE ANGIOTECH INTERNATIONAL AG (CH) 2005-06-09 WO disclosed
WO-2005051483-A2 ELECTRICAL DEVICES AND ANTI-SCARRING AGENTS ANGIOTECH INTERNATIONAL AG (CH) 2005-06-09 WO disclosed
WO-2005051444-A2 SOFT TISSUE IMPLANTS AND ANTI-SCARRING AGENTS ANGIOTECH INTERNATIONAL AG (CH) 2005-06-09 WO disclosed
WO-2004060346-A2 DRUG DELIVERY FROM RAPID GELLING POLYMER COMPOSITION ANGIOTECH INTERNATIONAL AG (CH) 2004-07-22 WO disclosed
WO-2004060405-A2 TISSUE REACTIVE COMPOUNDS AND COMPOSITIONS AND USES THEREOF ANGIOTECH INTERNATIONAL AG (CH) 2004-07-22 WO disclosed
EP-1235598-A2 COMPOSITIONS OF A COMBINATION OF RADIOACTIVE THERAPY AND CELL-CYCLE INHIBITORS Angiotech Pharmaceuticals, Inc. (CA) 2002-09-04 EP disclosed
WO-2001036007-A2 COMPOSITIONS OF A COMBINATION OF RADIOACTIVE THERAPY AND CELL-CYCLE INHIBITORS ANGIOTECH PHARMACEUTICALS, INC. (CA) 2001-05-25 WO disclosed